Thrombotic Disease Therapeutics Market Expected To Be Worth Over USD17 billion in 2010.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39094) has announced the addition of "Thrombotic Disease Therapeutics" to their offering.

Thrombotic diseases such as ischemic stroke and myocardial infarction remain the leading cause of death in the EU and US. We expect the prevalence of thrombotic diseases will grow at a rate higher than the population growth due to an increasing elderly population who are more susceptible to such conditions. Currently, anti-coagulants, anti-platelets, and thrombolytics are the three leading drug classes to be utilized for thrombotic disease treatments.

However, physician preference on usage of thrombolytics has been declining due to safety and efficacy concerns. Sanofi-aventis dominates the total market with two leading brands: Plavix, an anti-platelet co-marketed with Bristol-Myers Squibb, and Lovenox, an anti-coagulant. Both drugs dominate their respective drug classes in revenues and are expected to continue their dominance due to a lack of significant emerging drug launches through 2010. Barring expected patent disputes among leading drugs including Plavix and Lovenox, the market is expected to reach over $17 billion in 2010, steered by current brand name drugs.

Companies Mentioned Include:

--Abbott Laboratories

--AstraZeneca

--Bristol-Myers Squibb

--Centocor (Subsidiary of Johnson & Johnson)

--Eli Lilly and Co.

--Genentech, Inc.

--GlaxoSmithKline

--Menarini

--Merck & Co.

--Pfizer

--Pharmion

--Roche

--Sankyo

--sanofi-aventis

--Schering-Plough

--Shire Pharmaceuticals

--The Medicines Company

For more information visit http://www.researchandmarkets.com/reports/c39094